Lake Street analyst Frank Takkinen lowered the firm’s price target on Sight Sciences (SGHT) to $2.50 from $3 and keeps a Hold rating on the shares. Glaucoma market-wide headwinds continue to weigh on the outlook, thought the firm thinks Q1 will be the trough before sequential stabilization through year-end, the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences price target lowered to $4 from $5 at Stifel
- Sight Sciences: Hold Rating Amid Revenue Challenges and Reimbursement Progress
- Sight Sciences price target lowered to $3.50 from $5.50 at Piper Sandler
- Sight Sciences Faces Headwinds in Glaucoma and Dry Eye Markets, Hold Rating Maintained
- Sight Sciences Reports 2024 Results and 2025 Outlook